Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 3/20 | 0.43 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.38 |
| ▸ | RELA | Q04206 | 1/20 | 0.38 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.38 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.38 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.38 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3859184 | 0.87 | EGLN1 (0.46) | MAP4K4 | |
| SCHEMBL10131002 | 0.77 | GRM5 (0.54) | GRM5FFAR1FFAR4 | |
| SCHEMBL26262737 | 0.76 | GRM5 (0.54) | GRM5SMN1; SMN2MAPTNPC1RAB9A | |
| SCHEMBL5219755 | 0.76 | RAB9A (0.45) | SMN1; SMN2MAPTHIF1ANPC1NFKB1 | |
| SCHEMBL16086914 | 0.75 | GRM5 (0.49) | GRM5FFAR1FFAR4 | |
| SCHEMBL2560784 | 0.74 | FFAR1 (0.50) | GRM5FFAR1MAPT | |
| SCHEMBL162349 | 0.74 | FFAR1 (0.58) | FFAR1SMN1; SMN2MAPT | |
| SCHEMBL70602 | 0.72 | CHEK1 (0.63) | SMN1; SMN2MAPTNPC1NFKB1RAB9A | |
| SCHEMBL31588411 | 0.72 | CHEK1 (0.63) | SMN1; SMN2MAPTNPC1NFKB1RAB9A | |
| SCHEMBL19385063 | 0.72 | RAB9A (0.45) | GRM5SMN1; SMN2MAPTHIF1ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11912679-B2 | Aryl alkynamide derivatives | ASTELLAS PHARMA, INC. (JP) | 2024-02-27 | — | — | US | disclosed |
| US-11912679-B2 | Aryl alkynamide derivatives | ASTELLAS PHARMA, INC. (JP) | 2024-02-27 | — | — | US | disclosed |
| US-20240018113-A1 | ARYL ALKYNAMIDE DERIVATIVES | ASTELLAS PHARMA, INC. (JP) | 2024-01-18 | — | — | US | disclosed |
| US-20240018113-A1 | ARYL ALKYNAMIDE DERIVATIVES | ASTELLAS PHARMA, INC. (JP) | 2024-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240018113-A1 | ARYL ALKYNAMIDE DERIVATIVES | STING1, IRF3, TBK1 | GRM5 3369/4885FFAR1 2341/4885SMN1; SMN2 382/4885 |
| US-11912679-B2 | Aryl alkynamide derivatives | STING1, IRF3, TBK1 | GRM5 3369/4885FFAR1 2341/4885SMN1; SMN2 382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.